Miltenyi Biotec: Business Overview, Financials & Competitive Analysis
Miltenyi Biotec scores 8/10 on the AskCyborg Cyborg Score (Strong). Dominant position in cell separation technology with expanding presence in high-growth CAR-T therapy manufacturing, supported by strong private ownership and reinvestment model. The privately-held company maintains consistently high profitability that founder Stefan Miltenyi reinvests for growth. Miltenyi markets products in 68 countries with 29 global locations, delivering a comprehensive portfolio.
What is Miltenyi Biotec's industry? Miltenyi Biotec (miltenyibiotec.com) operates in Life Sciences Tools and Services. AskCyborg classifies Miltenyi Biotec under Life Sciences Tools and Services in its company registry.
Miltenyi Biotec is a German biotechnology company headquartered in Bergisch Gladbach that provides products and services for biomedical research, translational research, and clinical applications. The company achieved...
Cyborg Score thesis
Dominant position in cell separation technology with expanding presence in high-growth CAR-T therapy manufacturing, supported by...
Read the full analyst-debate transcript →Get the Latest Miltenyi Biotec Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMiltenyi Biotec Overview
Pro stress-test →Miltenyi Biotec is a German biotechnology company headquartered in Bergisch Gladbach that provides products and services for biomedical research, translational research, and clinical applications. The company achieved sales of €880 million in 2022 and is projected to exceed €1 billion in 2023. With more than 4,700 employees in 23 countries, the company focuses on advancing cellular therapy and cancer research.
Strategic Profile
Pro stress-test →Miltenyi Biotec holds a dominant position in the world market for cell separation, anchored by its proprietary MACS (Magnetic Cell Separation) technology using MACS microbeads, columns and separators for magnetic cell isolation. The company's products support the development of cellular therapies and aim to make cell therapy a more viable reality for patients. Hundreds of clinical trials rely on Miltenyi products, and the company developed a subsidiary (Miltenyi Biomedicine in 2019) focusing on cell therapies, with a tandem CAR T therapy for B-cell lymphomas currently in Phase II trials.
Competitive Landscape
Pro stress-test →Top competitors include Abcam, Sutro Biopharma, and Synthego. Miltenyi Biotec is positioned among industry leaders alongside Agilent Technologies, Illumina, and Thermo Fisher Scientific. However, Miltenyi's proprietary MACS technology and integrated product platform for cell therapy manufacturing differentiate it in the specialized cell separation and clinical-grade cell processing markets.
Industry Context
Miltenyi Biotec operates in Life Sciences Tools and Services.
Key facts
Founded: 1989 · Headquarters: Bergisch Gladbach, Germany · Employees: 4,700+ · Revenue: €880M (2022); projected >€1B (2023)